

# **ATTACHMENT B**



EV 698125511 US

Customer Copy

Label 11-F, April 2004



UNITED STATES POSTAL SERVICE®

Post Office To Addressee

ORIGINATOR'S COPY		POST OFFICE TO ADDRESSEE COPY	
1. Date of Mailing	2. Date of Delivery	3. Date of Mailing	4. Date of Delivery
5. Amount of Postage	6. Amount of Postage	7. Amount of Postage	8. Amount of Postage
9. Amount of Postage	10. Amount of Postage	11. Amount of Postage	12. Amount of Postage
13. Amount of Postage	14. Amount of Postage	15. Amount of Postage	16. Amount of Postage
17. Amount of Postage	18. Amount of Postage	19. Amount of Postage	20. Amount of Postage
21. Amount of Postage	22. Amount of Postage	23. Amount of Postage	24. Amount of Postage
25. Amount of Postage	26. Amount of Postage	27. Amount of Postage	28. Amount of Postage
29. Amount of Postage	30. Amount of Postage	31. Amount of Postage	32. Amount of Postage
33. Amount of Postage	34. Amount of Postage	35. Amount of Postage	36. Amount of Postage
37. Amount of Postage	38. Amount of Postage	39. Amount of Postage	40. Amount of Postage
41. Amount of Postage	42. Amount of Postage	43. Amount of Postage	44. Amount of Postage
45. Amount of Postage	46. Amount of Postage	47. Amount of Postage	48. Amount of Postage
49. Amount of Postage	50. Amount of Postage	51. Amount of Postage	52. Amount of Postage
53. Amount of Postage	54. Amount of Postage	55. Amount of Postage	56. Amount of Postage
57. Amount of Postage	58. Amount of Postage	59. Amount of Postage	60. Amount of Postage
61. Amount of Postage	62. Amount of Postage	63. Amount of Postage	64. Amount of Postage
65. Amount of Postage	66. Amount of Postage	67. Amount of Postage	68. Amount of Postage
69. Amount of Postage	70. Amount of Postage	71. Amount of Postage	72. Amount of Postage
73. Amount of Postage	74. Amount of Postage	75. Amount of Postage	76. Amount of Postage
77. Amount of Postage	78. Amount of Postage	79. Amount of Postage	80. Amount of Postage
81. Amount of Postage	82. Amount of Postage	83. Amount of Postage	84. Amount of Postage
85. Amount of Postage	86. Amount of Postage	87. Amount of Postage	88. Amount of Postage
89. Amount of Postage	90. Amount of Postage	91. Amount of Postage	92. Amount of Postage
93. Amount of Postage	94. Amount of Postage	95. Amount of Postage	96. Amount of Postage
97. Amount of Postage	98. Amount of Postage	99. Amount of Postage	100. Amount of Postage

CUSTOMER'S COPY		POST OFFICE TO ADDRESSEE COPY	
METHOD OF PAYMENT		Federal Agency Acct. No. or Postal Service Acct. No.	
Express Mail Control No. Add. No.		PHONE ( ) ( ) ( ) ( ) ( ) ( )	
FROM: (PLEASE PRINT)		TO: (PLEASE PRINT)	
PHONE ( ) ( ) ( ) ( ) ( ) ( )		COMMISSIONER FOR PATENTS	
2201 M ST NW		P.O. BOX 1450	
ALEXANDRIA, VA 22313-1450		ALEXANDRIA, VA 22313-1450	
L. Baskin No. 50821/5 MSB			
FOR PICKUP OR TRACKING: Visit <a href="http://www.usps.com">www.usps.com</a> or Call 1-800-222-1811		EMS	

THE UNITED STATES PATENT AND TRADEMARK  
OFFICE: PLEASE STAMP AND RETURN. THANK  
YOU.

Submitted: Amendment and Response (11 pgs.);  
Amendment Transmittal Letter (1 pg.); Certificate of  
Mailing by Express Mail Label EV698125511US;  
Postcard

Applicant: Shcherbakova et al.  
Serial No.: 11/531,161  
Filed: April 12, 2005  
Title: QUINAZOLINONE COMPOUNDS AS  
CALCIFYTICS  
Examiner: Tamthom Ngo Truong  
Mailed: March 15, 2007

Docket No.: 50821/5



**CERTIFICATE OF MAILING** ✓ **"EXPRESS MAIL"** (37 CFR 1.16,

Applicant(s): Sheherbakova et al.

Docket No.

50821/5

Application No.

11/531,161

Filing Date

April 12, 2005

Examiner

Tamthom Ngo Truong

Customer No.

32642

Group Art Unit

1624


Invention: **QUINAZOLINONE COMPOUNDS AS CALCILYTICS**

I hereby certify that the following correspondence:


Amendment and Response to Office Action (including the items listed below)

*(Identify type of correspondence)*

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

MAR. 15, 2007*(Date)*Kevin B. Laurence*(Typed or Printed Name of Person Mailing Correspondence)**(Signature of Person Mailing Correspondence)*EV698125511US*("Express Mail" Mailing Label Number)***Note: Each paper must have its own certificate of mailing.**

Transmitted: Amendment and Response to Office Action (11 pgs.)  
Amendment Transmittal Letter (1 pg.)  
Certificate of Mailing by "Express Mail" Label No. EV698125511US  
Postcard

<b>AMENDMENT TRANS. INITIAL LETTER (Large Entity)</b>				Docket No. <b>50821/5</b>	
Applicant(s): <b>Sheherbakova et al.</b>					
Application No. <b>11/531,161</b>	Filing Date <b>April 12, 2005</b>	Examiner <b>Tamthom Ngo Truong</b>	Customer No. <b>32642</b>	Group Art Unit <b>1624</b>	Confirmation No. <b>4723</b>
Invention: <b>QUINAZOLINONE COMPOUNDS AS CALCILYTICS</b>					
<u>COMMISSIONER FOR PATENTS:</u>					
Transmitted herewith is an amendment in the above-identified application. The fee has been calculated and is transmitted as shown below.					
<b>CLAIMS AS AMENDED</b>					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	18 -	20 =	0	x \$50.00	\$0.00
INDEP. CLAIMS	3 -	3 =	0	x \$200.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
<b>TOTAL ADDITIONAL FEE FOR THIS AMENDMENT</b>					<b>\$0.00</b>
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account <b>50-2375</b> <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17. <input type="checkbox"/> Payment by credit card. Form PTO-2038.					
<b>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</b>					
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;">             Signature         </div> <div style="width: 45%; text-align: right;">           Dated: <b>MAR. 15, 2007</b> </div> </div>					
<div style="display: flex;"> <div style="width: 45%; border: 1px solid black; padding: 5px;"> <b>Kevin B. Laurence</b>            Registration No. 38,219            Stoel Rives LLP            One Utah Center            201 South Main Street, Suite 1100            Salt Lake City, UT 84111            Telephone: 801-578-6932            Facsimile: 801-578-6999         </div> <div style="width: 50%; border: 1px solid black; padding: 5px; margin-left: 10px;">           I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____            _____            (Date)            _____            Signature of Person Mailing Correspondence            _____            Typed or Printed Name of Person Mailing Correspondence         </div> </div>					
CC:					

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.	:	11/531,161	Confirmation No.	4723
Applicant	:	Shcherbakova et al.		
Title	:	QUINAZOLINONE COMPOUNDS AS CALCILYTICS		
Filed	:	April 12, 2005		
TC/A.U.	:	1624		
Examiner	:	Tamthom Ngo Truong		
Customer No.	:	32642		

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE TO OFFICE ACTION

Dear Sir:

In response to the Office Action of January 16, 2007, please amend the above-identified application as follows:

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this paper.


**Remarks/Arguments** begin on page 8 of this paper.

## Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

Claim1 (currently amended) A compound having the chemical formula:



wherein:

R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> is each independently chosen from: H, halogen, CN, CF<sub>3</sub>, OCF<sub>3</sub>, lower alkyl, lower alkoxy, NH-acetyl, NH-lower alkyl, NH-alkylaryl, N(lower alkyl)<sub>2</sub>, C(O)OH, C(O)O-lower alkyl, C(O)NH-lower alkyl, C(O)N(lower alkyl)<sub>2</sub>, OH, OC(O)-lower alkyl, OC(O)-lower alkylamino, OC(O)-lower alkyl-N(lower alkyl)<sub>2</sub>, and OP(O)(OH)<sub>2</sub>;

R<sup>4</sup> is chosen from: H, halogen, CN, CF<sub>3</sub>, OCF<sub>3</sub>, lower alkyl, lower alkoxy, NH-acetyl, NH-lower alkyl, NH-alkylaryl, N(lower alkyl)<sub>2</sub>, C(O)OH, C(O)O-lower alkyl, C(O)NH-lower alkyl, C(O)N(lower alkyl)<sub>2</sub>, OH, OC(O)-lower alkyl, OC(O)-lower alkylamino, OC(O)-lower alkyl-N(lower alkyl)<sub>2</sub>, and OP(O)(OH)<sub>2</sub>;

X<sup>1</sup> is selected from one of C and N, such that when X<sup>1</sup> is N, then R<sup>4</sup> is absent;

R<sup>5</sup> is chosen from: H, a thienyl, styryl, pyridyl and phenyl group, wherein the thienyl, styryl, pyridyl and phenyl group is optionally substituted with 1 to 3 substituents chosen from: H, halogen, CN, CF<sub>3</sub>, OCF<sub>3</sub>, lower alkyl, NH-alkylaryl, N(lower alkyl)<sub>2</sub>, OH, OC(O)-lower alkyl, OC(O)-lower alkylamino, OC(O)-lower alkyl-NH-lower alkyl, OC(O)-lower alkyl-N(lower alkyl)<sub>2</sub>, and OP(O)(OH)<sub>2</sub>;

$R^6$  comprises  $-(CH_2)_n-X^2-R^7$  wherein  $n$  is 1, [[or]] 2 or 3,  $X^2$  is O, C(O), CH(OH), lower-alkyl or a single bond, and

$R^7$  is chosen from a pyridyl and a phenyl group, wherein  $R^7$  is optionally substituted with 1 to 3 substituents chosen from: H, halogen, CN,  $OCF_3$ , unsubstituted lower alkyl, NH-alkylaryl, OC(O)-lower alkyl, OC(O)-lower alkylamino, OC(O)-lower alkyl-N(lower alkyl)<sub>2</sub>, and OP(O)(OH)<sub>2</sub>;

or a pharmaceutically acceptable salt or complex thereof;

wherein the compound has a Calcium Receptor Inhibitor Assay  $IC_{50}$  value of no greater than 30  $\mu$ M or lower.

Claim 2 (original) A compound according to claim 1, wherein  $R^1$ ,  $R^2$ ,  $R^3$ , and  $R^4$  are independently selected from one of hydrogen, halogen, lower alkyl, OH and OP(O)(OH)<sub>2</sub>.

Claim 3 (original) A compound according to claim 2, wherein said halogen is selected from one of fluorine and chlorine.

Claim 4 (original) A compound according to claim 2, wherein lower alkyl is methyl.

Claim 5 (original) A compound according to claim 2 wherein,  $R^1$  is selected from one of hydrogen and methyl.

Claim 6 (original) A compound according to claim 2, wherein  $R^2$  is selected from one of hydrogen, fluorine, chlorine, hydroxy, and methyl.

Claim 7 (original) A compound according to claim 2, wherein  $R^3$  is selected from one of hydrogen and chlorine.

Claim 8 (original) A compound according to claim 2, wherein  $R^4$  is selected from one of hydrogen, hydroxy, and methyl.

Claim 9 (original) A compound according to claim 1, wherein  $X^1$  is carbon.

Claim 10 (original) A compound according to claim 1, wherein  $R^5$  is phenyl optionally substituted with 1 or 2 hydroxy.

Claim 11 (original) A compound according to claim 1, wherein  $R^6$  further comprises the group  $-(CH_2)_n-X^2-R^7$ ;  
wherein n is 1 or 2;  
 $X^2$  is a single bond, and  
 $R^7$  is phenyl optionally substituted with 1 or 2 halogens.

Claim 12 (original) A compound according to claim 11, wherein n is 2 and said halogens are selected from one of fluorine and chlorine.

Claim 13 (original) A pharmaceutical composition comprising a compound according to claim 1 and pharmaceutically acceptable diluent or excipient.

Claim 14 (previously presented) A method of treating a disease or disorder characterized by abnormal bone or mineral homeostasis chosen from: osteosarcoma, periodontal disease, fracture healing, osteoarthritis, rheumatoid arthritis, Paget's disease, humoral hypercalcemia malignancy, and osteoporosis, comprising the administration to a subject in need of treatment thereof an effective amount of a compound according to claim 1.

Claim 15 (cancelled)



Claim 16 (original) A method according to claim 14, wherein the bone or mineral disease or disorder is osteoporosis.

Claim 17 (previously presented) A method of increasing serum parathyroid hormone levels in mammals for treatment of a disease or disorder chosen from: osteosarcoma, periodontal disease, fracture healing, osteoarthritis, rheumatoid arthritis, Paget's disease, humoral hypercalcemia malignancy, and osteoporosis, which comprises the administration to a subject which may be benefited thereby an effective amount of a compound according to claim 1 sufficient to increase serum parathyroid hormone levels.

Claim 18 (original) A method for preparing 2,3,5,6,7,8-substituted 3*H*-quinazolin-4-ones by reacting 2,4,5,6,7,8-substituted benzo[d][1,3]oxazin-4-ones with primary amines under microwave irradiation conditions.

Claim 19 (previously presented) A compound selected from one of:

- 2-(2-hydroxy-phenyl)-3-phenethyl-3*H*-quinazolin-4-one;
- 2-(2,5-dihydroxy-phenyl)-3-phenethyl-3*H*-quinazolin-4-one;
- 2-(3-hydroxy-phenyl)-3-phenethyl-3*H*-quinazolin-4-one;
- 2-(2-hydroxy-phenyl)-3-(2-phenoxy-ethyl)-3*H*-quinazolin-4-one;
- 3-[2-(4-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;
- 3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;
- 3-[2-(2-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;
- 3-[2-(3-chloro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;
- 3-[2-(2-chloro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;
- 2-(2-hydroxy-phenyl)-3-[2-(2-methoxy-phenyl)-ethyl]-3*H*-quinazolin-4-one;
- 2-(2-hydroxy-phenyl)-3-(2-*p*-tolyl-ethyl)-3*H*-quinazolin-4-one;
- 2-(2-hydroxy-phenyl)-6-methyl-3-phenethyl-3*H*-quinazolin-4-one;
- 6-fluoro-2-(2-hydroxy-phenyl)-3-phenethyl-3*H*-quinazolin-4-one;

6-chloro-2-(2-hydroxy-phenyl)-3-phenethyl-3*H*-quinazolin-4-one;  
2-(2-hydroxy-phenyl)-3-phenethyl-5-phenethylamino-3*H*-quinazolin-4-one;  
2-(2-hydroxy-phenyl)-5-methyl-3-phenethyl-3*H*-quinazolin-4-one;  
7-chloro-2-(2-hydroxy-phenyl)-3-phenethyl-3*H*-quinazolin-4-one;  
2-(2-hydroxy-phenyl)-8-methyl-3-phenethyl-3*H*-quinazolin-4-one;  
6-fluoro-3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;  
6-fluoro-3-[2-(2-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;  
7-fluoro-3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;  
3-[2-(2-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-5-methyl-3*H*-quinazolin-4-one;  
3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-5-methyl-3*H*-quinazolin-4-one;  
3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-6-methyl-3*H*-quinazolin-4-one;  
3-[2-(2-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-6-methyl-3*H*-quinazolin-4-one;  
6-chloro-3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;  
6-chloro-3-[2-(2-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;  
3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-6-methoxy-3*H*-quinazolin-4-one;  
3-[2-(3-fluoro-phenyl)-ethyl]-6-hydroxy-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;  
acetic acid 2-{6-fluoro-3-[2-(3-fluoro-phenyl)-ethyl]-4-oxo-3,4-dihydro-quinazolin-2-yl}-  
phenyl ester;  
3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-8-methoxy-3*H*-quinazolin-4-one;  
isobutyric acid 2-{6-fluoro-3-[2-(3-fluoro-phenyl)-ethyl]-4-oxo-3,4-dihydro-quinazolin-2-  
yl}-phenyl ester;  
sodium salt of 6-fluoro-3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-  
4-one;  
8-chloro-2-(2-hydroxy-phenyl)-3-phenethyl-3*H*-quinazolin-4-one;  
7-chloro-3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;  
7-chloro-3-[2-(2-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;  
2-(2-hydroxy-phenyl)-3-(2-pyridin-3-yl-ethyl)-3*H*-quinazolin-4-one;  
6-fluoro-2-(2-hydroxy-phenyl)-3-(2-pyridin-3-yl-ethyl)-3*H*-quinazolin-4-one;  
2-(2-hydroxy-phenyl)-3-phenethyl-3*H*-pyrido[2,3-*d*]pyrimidin-4-one;

3-[2-(3-fluoro-phenyl)-ethyl]-2-(2-hydroxy-phenyl)-3*H*-pyrido[2,3-*d*]pyrimidin-4-one;  
3-(1,1-dimethyl-3-phenyl-propyl)-6-fluoro-2-(2-hydroxy-phenyl)-3*H*-quinazolin-4-one;  
methylamino-acetic acid 2-[6-fluoro-3-[2-(3-fluoro-phenyl)-ethyl]-4-oxo-3,4-dihydro-  
quinazolin-2-yl]-phenyl ester hydrochloride;  
6-fluoro-2-(2-hydroxy-phenyl)-3-(2-phenyl-propyl)-3*H*-quinazolin-4-one;  
6-fluoro-2-(2-hydroxy-phenyl)-3-(*R*-2-phenyl-propyl)-3*H*-quinazolin-4-one;  
6-fluoro-2-(2-hydroxy-phenyl)-3-(*S*-2-phenyl-propyl)-3*H*-quinazolin-4-one; and  
6-fluoro-2-(2-hydroxy-phenyl)-3-(3-phenyl-propyl)-3*H*-quinazolin-4-one  
or a pharmaceutically acceptable salt or complex thereof.

### **REMARKS/ARGUMENTS**

This Amendment is submitted in response to the Office Action mailed January 16, 2007. At that time claims 1-14 and 16-19 were pending in the application. In the Office Action, the Examiner withdrew the previous rejection under 35 U.S.C. §112, ¶¶ 1 and 2. The Examiner also found claim 19 to be allowable. However, the Examiner rejected claims 1-14 and 16-19 under 35 U.S.C. §112 ¶ 2 as being indefinite. Additionally, the Examiner rejected claims 1-3, 5-9 and 13 under 35 U.S.C. §102(b) as being anticipated by U.S. Patent No. 4,710,502 issued to Wright, Jr. et al. (hereinafter "Wright, Jr.").

By this Amendment, claim 1 has been amended. Accordingly, claims 1-14 and 16-19 are presented for reconsideration by the Examiner.

### **REJECTION OF CLAIMS 1-14 and 16-19 UNDER 35 U.S.C. §112, ¶ 2**

In the Office Action, the Examiner rejected claims 1-14 and 16-19 under 35 U.S.C. §112 ¶ 2 as being indefinite. See Office Action, page 2. The Applicants respectfully traverse this rejection.

The Examiner rejected claims 1-14 and 16-19 because of the element "the compound has a Calcium Receptor Inhibitor Assay  $IC_{50}$  value of 30  $\mu M$  or lower." Applicants initially note that claim 19 does not depend from claim 1 and should not be included in the rejection under §112. By this Amendment, claim 1 was amended to recite "the compound has a Calcium Receptor Inhibitor Assay  $IC_{50}$  value of no greater than 30  $\mu M$ ." Exemplary support for this amendment can be found in the Present Application, page 66, lines 9-13. Therefore, no new matter has been added.

The Examiner has presented essentially three reasons why the element is allegedly indefinite. First, the Examiner argues that the original phrase "or lower" did not have definite metes and bounds because it technically includes an  $IC_{50}$  value of zero. See Office Action, page 2. Claim 1 was amended to recite an " $IC_{50}$  value of no greater than 30  $\mu M$ ," thus avoiding the Examiner's concern that the claim covers  $IC_{50}$  values of zero.

Second, the Examiner argues, "[i]t is not clear what assay conditions are needed to obtain such an IC<sub>50</sub> value. Thus, various factors could yield the same IC<sub>50</sub> value for different set[s] of compounds." See Office Action, pages 2-3. As pointed out in the Amendment dated December 14, 2006, there is only one assay disclosed in the Present Application, and the conditions and procedure described is the assay are to be used to obtain the IC<sub>50</sub> value recited in the claims. The assay used to determine the IC<sub>50</sub> value for a claimed compound is clearly set forth on page 64, line 27 to page 66, line 13 and is titled "Calcium Receptor Inhibitor Assay." One having skill in the art would be able to routinely perform the assay using the procedure described to determine the IC<sub>50</sub> value as claimed. Therefore, it is clear what assay conditions are needed to obtain the IC<sub>50</sub> value recited in claim 1, and the element meets the requirements of 35 U.S.C. §112, second paragraph.

Third, the Examiner argues that the element provides functional language and does not "define any structural attributes." See Office Action, page 3. According to MPEP §2173.05(g), "There is nothing inherently wrong with defining some part of an invention in functional terms. Functional language does not, in and of itself, render a claim improper" (*citing In re Swinehart*, 439 F.2d 210 (CCPA 1971)). "A functional limitation is often used in association with an element, ingredient, or step of a process to define a particular capability or purpose that is served by the recited element, ingredient or step." MPEP §2173.05(g). In the present case, the recitation of "the compound has a Calcium Receptor Inhibitor Assay IC<sub>50</sub> value of no greater than 30  $\mu$ M" is used in association with the claimed structure to "define a particular capability...that is served by the recited [structure]."

Not only is this consonant with MPEP §2173.05(g), but it follows the direction provided in *In re Barr*, 444 F.2d 588, 595 (CCPA 1971), which states:

The real issue in any such case [of determining definiteness] is not whether the recital is 'functional' or 'negative,' but whether the recital sets definite boundaries on the patent protection sought – that is, whether

those skilled in the relevant art can determine what the claim does or does not read on.

Judged by this standard, it is clear that the element of the claimed compound having an "IC<sub>50</sub> value of no greater than 30  $\mu$ M" complies with the second paragraph of §112 because, as described above, the specification provides a clear assay providing details necessary for one skilled in the art to determine whether or not the claim reads on a given compound. Therefore, the element meets the requirements of 35 U.S.C. §112, second paragraph. Withdrawal of this rejection is respectfully requested.

**REJECTION OF CLAIMS 1-3, 5-9 and 13 UNDER 35 U.S.C. §102(b)**

Claims 1-3, 5-9 and 13 were rejected under 35 U.S.C. §102(b) as being anticipated by Wright, Jr. See Office Action, page 3. Applicants respectfully traverse this rejection.

It is well settled that a claim is anticipated under 35 U.S.C. § 102(b) only if "each and every element as set forth in the claim is found, either expressly or inherently described, in a single prior art reference." MPEP §2131, citing *Verdegaal Bros. v. Union Oil Co. of California*, 814 F.2d 628, 631, 2 USPQ2d 1051, 1053 (Fed. Cir. 1987). "The identical invention must be shown in as complete detail as is contained in the ... claim." MPEP §2131, citing *Richardson v. Suzuki Motor Co.*, 868 F.2d 1226, 1236, 9 USPQ2d 1913, 1920 (Fed. Cir. 1989).

As a result of this paper, claim 1 was amended so that n is 1, 2 or 3 and X<sup>2</sup> does not include lower alkyl. Exemplary support for this amendment can be found on page 39 of the Present Application, compound 64, demonstrating a compound wherein n is 3. Therefore, no new matter has been added. Claims 1-3, 5-9 and 13 do not read on the compounds disclosed in Wright, Jr., namely, 6-chloro-3-[4-(3-pyridyl)butyl]-4(3H)-quinazolinone and 6-bromo-3-[4-(3-pyridyl)butyl]-4(3H)-quinazolinone (Table 1) because n  $\neq$  4 and X<sup>2</sup> does not include lower alkyl. Because each and every claim element is not disclosed by Wright, Jr., the claims at issue are not anticipated. Withdrawal of this rejection is respectfully requested.

**CONCLUSION**

Applicants respectfully assert that claims 1-14 and 16-19 are patentably distinct from the cited reference, and request that a timely Notice of Allowance be issued in this case. If there are any remaining issues preventing allowance of the pending claims that may be clarified by telephone, the Examiner is requested to call the undersigned.

Respectfully submitted,

A handwritten signature in cursive script, reading "Kevin B. Laurence", written in dark ink over a horizontal line.

Kevin B. Laurence  
Reg. No. 38,219  
Attorney for Applicant(s)

Date: March 15, 2007

STOEL RIVES LLP  
One Utah Center  
201 South Main Street, Suite 1100  
Salt Lake City, UT 84111  
Telephone: (801) 578-6932  
Facsimile: (801) 578-6999